Blueshift Asset Management LLC acquired a new stake in shares of Haemonetics Co. (NYSE:HAE) in the 2nd quarter, HoldingsChannel reports. The institutional investor acquired 9,264 shares of the medical instruments supplier’s stock, valued at approximately $617,000.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Dean Capital Management bought a new position in Haemonetics during the second quarter valued at $912,000. Geode Capital Management LLC grew its holdings in Haemonetics by 38.9% during the second quarter. Geode Capital Management LLC now owns 857,591 shares of the medical instruments supplier’s stock valued at $57,149,000 after purchasing an additional 240,178 shares during the period. ProShare Advisors LLC grew its holdings in Haemonetics by 286.0% during the second quarter. ProShare Advisors LLC now owns 18,779 shares of the medical instruments supplier’s stock valued at $1,251,000 after purchasing an additional 13,914 shares during the period. Golden State Equity Partners bought a new position in shares of Haemonetics in the second quarter worth $748,000. Finally, Profund Advisors LLC boosted its holdings in shares of Haemonetics by 44.3% in the second quarter. Profund Advisors LLC now owns 4,893 shares of the medical instruments supplier’s stock worth $326,000 after acquiring an additional 1,501 shares during the period. 98.44% of the stock is owned by institutional investors and hedge funds.
A number of research firms have recently commented on HAE. Needham & Company LLC reaffirmed a “buy” rating and issued a $86.00 price target on shares of Haemonetics in a report on Tuesday, June 29th. Zacks Investment Research raised Haemonetics from a “sell” rating to a “hold” rating and set a $63.00 price target for the company in a report on Wednesday, August 18th. began coverage on Haemonetics in a report on Thursday, June 17th. They issued a “buy” rating and a $75.00 price target for the company. Finally, Citigroup started coverage on Haemonetics in a report on Thursday, June 17th. They issued a “buy” rating for the company. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, Haemonetics currently has a consensus rating of “Buy” and an average target price of $87.50.
Haemonetics (NYSE:HAE) last released its quarterly earnings results on Tuesday, August 10th. The medical instruments supplier reported $0.50 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.45 by $0.05. Haemonetics had a return on equity of 17.51% and a net margin of 7.14%. The business had revenue of $228.53 million for the quarter, compared to the consensus estimate of $225.54 million. On average, equities analysts expect that Haemonetics Co. will post 2.77 earnings per share for the current fiscal year.
Haemonetics Company Profile
Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. It operates through the following segments: Plasma, Blood Center, Hospital, and Corporate. The Plasma segment offers automated plasma collection and donor management software systems.
Featured Article: Investing strategies using the yield curve
Want to see what other hedge funds are holding HAE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Haemonetics Co. (NYSE:HAE).
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.